EUVIMEDEUVIMED entdecken
Crossref

Bimekizumab for treatment of moderate to severe hidradenitis suppurativa: a real-world, single-centre case series

Emily K Pender, Emma Carroll iD, Maria-Alexandra Visan, Rosalind Hughes, Brian Kirby

Clinical and Experimental Dermatology · 24.07.2026 · 51 (8) · 1478-1481

DOI: 10.1093/ced/llag140 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical and Experimental Dermatology, online erschienen am 23.04.2026. Verfasst von Emily K Pender und 4 weiteren Autor:innen. Beteiligte Einrichtung: Charles Centre, Department of Dermatology, St Vincent's University Hospital, Dublin, Ireland. Hauptthemen laut MEDLINE: Hidradenitis Suppurativa, Antibodies, Monoclonal, Humanized, Dermatologic Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 9 Literaturangaben. Gefördert von: City of Dublin Skin, Cancer Hospital Charity.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Bimekizumab is a humanized monoclonal antibody to interleukins-17A and -17F, licensed in 2023 for the treatment of moderate to severe hidradenitis suppurativa (HS). This retrospective case series discusses 15 patients who were treated with bimekizumab for HS. Of the total, 74% were female. The mean age of the patients was 42 years; 87% had Hurley stage III HS and the mean baseline International Hidradenitis Suppurativa Severity Score System score was 20.13. All were biologic experienced and 11/15 were taking concomitant medications for the treatment of HS. At 16 weeks, as calculated by HS Clinical Response or HS Physician Global Assessment, 10/15 (67%) patients responded to bimekizumab. The mean Dermatology Life Quality Index fell by nine points. One patient experienced secondary failure at 9 months. Response rates in this group at week 16 were higher than those seen in phase III clinical trials, despite previous biologic exposure in all patients. While concomitant HS medication may play a role in this higher response rate, bimekizumab is an important treatment option for moderate to severe HS.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hidradenitis SuppurativaAntibodies, Monoclonal, HumanizedDermatologic AgentsHumansFemaleAdultRetrospective StudiesSeverity of Illness IndexMaleMiddle AgedTreatment OutcomeQuality of Life

Substanzen

Antibodies, Monoclonal, HumanizedDermatologic Agents

Autor:innen und Institutionen

  • Charles Centre, Department of Dermatology, St Vincent's University Hospital, Dublin, Ireland.
  • Charles Institute of Dermatology, School of Medicine, University College Dublin, Dublin, Ireland.

ORCID-Profile: Emma Carroll

Förderung

  • City of Dublin Skin
  • Cancer Hospital Charity

Zitieren

APA

Pender, E. K., Carroll, E., Visan, M. A., Hughes, R., & Kirby, B. (2026). Bimekizumab for treatment of moderate to severe hidradenitis suppurativa: a real-world, single-centre case series. Clinical and Experimental Dermatology, 51(8), 1478-1481. https://doi.org/10.1093/ced/llag140

Vancouver

Pender EK, Carroll E, Visan MA, Hughes R, Kirby B. Bimekizumab for treatment of moderate to severe hidradenitis suppurativa: a real-world, single-centre case series. Clinical and Experimental Dermatology. 2026;51(8):1478-1481. doi:10.1093/ced/llag140

BibTeX
@article{Pender2026,
  author = {Pender, Emily K and Carroll, Emma and Visan, Maria-Alexandra and Hughes, Rosalind and Kirby, Brian},
  title = {Bimekizumab for treatment of moderate to severe hidradenitis suppurativa: a real-world, single-centre case series},
  journal = {Clinical and Experimental Dermatology},
  year = {2026},
  volume = {51},
  number = {8},
  pages = {1478--1481},
  doi = {10.1093/ced/llag140}
}
Kostenlos starten →